TearCare in Young Adults

Starting soon · Not applicable

Conditions studied: Meibomian Gland Dysfunction (Disorder)

In brief

This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.

Key facts

Study ID

NCT07579156

Run by

University of Alabama at Birmingham

People needed

45

Starts

2026-08-01

Expected to finish

2027-12-01

Last updated by the study team

2026-05-11

Who can join

Age: 18 and older, up to 29. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years but <30 years of age
• Non-invasive Keratograph break-up time (NIKBUT) <10 seconds in at least one eye
• Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid
• OSDI ≥23

You may not qualify if…

• Contact lens wear within two weeks of study enrollment or planned during study period
• Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20/40) in either eye
• Previous or current diagnosis of any autoimmune condition
• Use of any of the following medications within 60 days of enrollment:
• Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)
• Xiidra®
• Miebo®
• Tyrvaya®
• Tryptyr®
• Use of topical ocular steroids within 30 days of enrollment
• Use of any other topical ophthalmic drop, excluding artificial tears, within 7 days
• Use of oral tetracyclines or oral azithromycin within 30 days
• Present or past use of oral isotretinoin
• Any of the following procedural treatments for MGD in the past:
• LipiFlow®
• TearCare®
• iLux®
• Intense pulsed light (IPL)
• Previous intraocular surgery within 6 months of enrollment
• Previous refractive surgery within 2 years of enrollment
• Current or planned pregnancy during the study period
• Current or planned lactation during the study period
• Females of childbearing potential who are not using effective contraception
• Dose modification of oral antihistamines or antidepressants within 30 days of enrollment
• Current enrollment or enrollment within 60 days in any other study of an investigational drug or device

Where it is running

• University of Alabama at Birmingham, School of Optometry, Clinical Eye Research Facility — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.